Research
Epitranscriptomics & Cancer Adaptation : A.David

Activities

Our research work focuses on the contribution of post-transcriptional mechanisms on cancer cell adaptation, in particular RNA epigenetic & translational control.

More..

Zotero public











Title  Creator  Group name  Publishing year 
Switch to fulvestrant and palbociclib versus no switch in advanced breast cancer with rising ESR1 mutation during aromatase inhibitor and palbociclib therapy (PADA-1): a randomised, open-label, multicentre, phase 3 trial Bidard et al. EquipePC 2022-11
Randomised, open-label, multicentric phase III trial to evaluate the safety and efficacy of palbociclib in combination with endocrine therapy, guided by ESR1 mutation monitoring in oestrogen receptor-positive, HER2-negative metastatic breast cancer patients: study design of PADA-1 Berger et al. EquipePC 2022-03-03
[2021 update of the GEFPICS' recommendations for HER2 status assessment in invasive breast cancer in France] Franchet et al. EquipeELC 2021-08-12
A whole-genome sequence and transcriptome perspective on HER2-positive breast cancers Ferrari et al. EquipeMY 07 13, 2016
Coexpression of androgen receptor and FOXA1 in nonmetastatic triple-negative breast cancer: ancillary study from PACS08 trial Guiu et al. EquipeELC 2015
[Pre-analytical stage for biomarker assessment in breast cancer: 2014 update of the GEFPICS' guidelines in France] MacGrogan et al. EquipeELC Oct 2014
[2014 update of the GEFPICS' recommendations for HER2 status determination in breast cancers in France] Penault-Llorca et al. EquipeELC Oct 2014
HER2-positive breast cancer: ¹?F-FDG PET for early prediction of response to trastuzumab plus taxane-based neoadjuvant chemotherapy Humbert et al. EquipeELC Aug 2014


© Institut de Recherche en Cancérologie de Montpellier - 2011 - Tous droits réservés - Mentions légales - Connexion - Conception : ID Alizés